![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 1
Zeitschriftenartikel
Harbeck, N. 
ORCID: https://orcid.org/0000-0002-9744-7372; Modi, S.; Pusztai, L.; Ohno, S.; Wu, J.; Kim, S.-B.; Yoshida, A.; Fabi, A.; Cao, X.; Joseph, R.; Li, R.; Żurawski, B.; Escrivá-de-Romaní, S. ORCID: https://orcid.org/0000-0001-7816-7589; Meneguetti, R.; Supavavej, A.; Chen, S.-C.; Liu, Z.; Kelly, C.; Curigliano, G. ORCID: https://orcid.org/0000-0003-1781-2518; Symmans, W.F. ORCID: https://orcid.org/0000-0002-1526-184X; Gufran, M.; Ke, J.; Konpa, A.; Herbolsheimer, P. und Boileau, J.-F.
(2025):
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
In: Annals of Oncology [Forthcoming]
ORCID: https://orcid.org/0000-0002-9744-7372; Modi, S.; Pusztai, L.; Ohno, S.; Wu, J.; Kim, S.-B.; Yoshida, A.; Fabi, A.; Cao, X.; Joseph, R.; Li, R.; Żurawski, B.; Escrivá-de-Romaní, S. ORCID: https://orcid.org/0000-0001-7816-7589; Meneguetti, R.; Supavavej, A.; Chen, S.-C.; Liu, Z.; Kelly, C.; Curigliano, G. ORCID: https://orcid.org/0000-0003-1781-2518; Symmans, W.F. ORCID: https://orcid.org/0000-0002-1526-184X; Gufran, M.; Ke, J.; Konpa, A.; Herbolsheimer, P. und Boileau, J.-F.
(2025):
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial.
In: Annals of Oncology [Forthcoming]